

# Daniel V Catenacci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1205438/publications.pdf>

Version: 2024-02-01

126  
papers

10,048  
citations

66234

42  
h-index

38300

95  
g-index

129  
all docs

129  
docs citations

129  
times ranked

11482  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma. ESMO Open, 2022, 7, 100360.  | 2.0 | 5         |
| 2  | Correlation of circulating tumor DNA (ctDNA) with clinical outcomes in appendiceal cancers (AC).. Journal of Clinical Oncology, 2022, 40, 29-29.  | 0.8 | 1         |
| 3  | CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME).. Journal of Clinical Oncology, 2022, 40, TPS377-TPS377.   | 0.8 | 0         |
| 4  | Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.. Journal of Clinical Oncology, 2022, 40, TPS365-TPS365.  | 0.8 | 5         |
| 5  | Impact of hyperthermic intraperitoneal chemotherapy on genomic heterogeneity of peritoneal metastases in stage IV gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 312-312.  | 0.8 | 1         |
| 6  | A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, TPS219-TPS219.   | 0.8 | 2         |
| 7  | MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma- Trial in progress.. Journal of Clinical Oncology, 2022, 40, TPS371-TPS371.  | 0.8 | 7         |
| 8  | Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for advanced upper GI cancers.. Journal of Clinical Oncology, 2022, 40, 316-316.                    | 0.8 | 0         |
| 9  | Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review. JCO Precision Oncology, 2022, 6, e2100337.   | 1.5 | 4         |
| 10 | Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor- Amplified Gastroesophageal Cancer: Retrospective Global Experience. Journal of Clinical Oncology, 2022, 40, 2458-2467.   | 0.8 | 9         |
| 11 | Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. Tumori, 2021, 107, 150-159.   | 0.6 | 8         |
| 12 | Morphologic and molecular analysis of early-onset gastric cancer. Cancer, 2021, 127, 103-114.   | 2.0 | 18        |
| 13 | MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncology, 2021, 17, 1155-1164.   | 1.1 | 64        |
| 14 | Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 1777-1785.   | 0.7 | 4         |
| 15 | Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. Journal of Clinical Oncology, 2021, 39, TPS264-TPS264.                | 0.8 | 4         |
| 16 | Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)- ILUSTRO Cohort 3.. Journal of Clinical Oncology, 2021, 39, TPS260-TPS260.   | 0.8 | 5         |
| 17 | A PERFECT Biomarker-focused Study of Neoadjuvant IO for Esophagogastric Cancer. Clinical Cancer Research, 2021, 27, 3269-3271.  | 3.2 | 1         |
| 18 | Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. Journal of Clinical Oncology, 2021, 39, 4069-4069. | 0.8 | 1         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).. Journal of Clinical Oncology, 2021, 39, 4010-4010.           | 0.8 | 27        |
| 20 | Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.. Journal of Clinical Oncology, 2021, 39, e16063-e16063.                               | 0.8 | 6         |
| 21 | Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instabilityâ€“High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncology, 2021, 7, 895.                     | 3.4 | 184       |
| 22 | Structural Racism and <i>JAMA Network Open</i>. JAMA Network Open, 2021, 4, e2120269.  | 2.8 | 17        |
| 23 | Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. ESMO Open, 2021, 6, 100200.  | 2.0 | 11        |
| 24 | Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. Oncologist, 2021, 26, e1704-e1729.  | 1.9 | 14        |
| 25 | Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, irinotecan, and ctDNA. Clinical Cancer Research, 2021, 27, clincanres.2777.2021.  | 3.2 | 0         |
| 26 | Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation. JAMA Oncology, 2021, 7, 1669.   | 3.4 | 194       |
| 27 | Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Annals of Surgical Oncology, 2021, 28, 4433-4443.  | 0.7 | 4         |
| 28 | Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).. Journal of Clinical Oncology, 2021, 39, 160-160. | 0.8 | 64        |
| 29 | MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinomaâ€“Trial in Progress.. Journal of Clinical Oncology, 2021, 39, TPS252-TPS252.                   | 0.8 | 16        |
| 30 | Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discovery, 2021, 11, 308-325.  | 7.7 | 49        |
| 31 | Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence. Cancers, 2021, 13, 5929.  | 1.7 | 8         |
| 32 | Evaluating the Value of a New Prediction Model for Gastric Cancer. JAMA Network Open, 2021, 4, e2137148.   | 2.8 | 1         |
| 33 | Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research, 2020, 26, 846-854.  | 3.2 | 90        |
| 34 | Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy. JAMA Oncology, 2020, 6, e193531.   | 3.4 | 16        |
| 35 | Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotypeâ€“Guided Dosing. Clinical Cancer Research, 2020, 26, 18-24.                               | 3.2 | 10        |
| 36 | Complete Response in a Patient With Chemorefractory <i>EGFR</i>-Amplified, PD-L1â€“Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Antiâ€“PD-1 Monoclonal Antibody Therapy. JCO Precision Oncology, 2020, 4, 1180-1186.                                 | 1.5 | 6         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Tackling diversity within diversity. <i>Annals of Oncology</i> , 2020, 31, 970-972.   | 0.6 | 1         |
| 38 | Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 6453-6463.  | 3.2 | 92        |
| 39 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.  | 5.1 | 620       |
| 40 | Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 2677-2694.  | 0.8 | 169       |
| 41 | Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 671-684.   | 5.1 | 923       |
| 42 | First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1237-1246.  | 3.2 | 61        |
| 43 | Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2418-2426.   | 0.8 | 55        |
| 44 | Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22â€“05): a single-arm, phase 1bâ€“2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1066-1076.   | 5.1 | 130       |
| 45 | Evaluation of the Association of Perioperative <i>UGT1A1</i> Genotypeâ€“Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma. <i>JAMA Network Open</i> , 2020, 3, e1921290. | 2.8 | 26        |
| 46 | The Chicago Consensus on peritoneal surface malignancies: Standards. <i>Cancer</i> , 2020, 126, 2516-2524.  | 2.0 | 7         |
| 47 | The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. <i>Cancer</i> , 2020, 126, 2553-2560.  | 2.0 | 11        |
| 48 | The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases. <i>Cancer</i> , 2020, 126, 2534-2540.  | 2.0 | 17        |
| 49 | The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. <i>Cancer</i> , 2020, 126, 2525-2533.  | 2.0 | 35        |
| 50 | Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097411.   | 1.4 | 12        |
| 51 | Impact of frontline doublet versus triplet therapy on clinical outcomes: Exploratory analysis from the RAINBOW study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4543-4543.   | 0.8 | 3         |
| 52 | Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4561-4561.  | 0.8 | 3         |
| 53 | Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GE) cancer by line of therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 430-430.  | 0.8 | 20        |
| 54 | Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS468-TPS468.   | 0.8 | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019, 25, 7035-7045.  | 3.2 | 152       |
| 56 | The Time for Mainstreaming Germline Testing for Patients With Breast Cancer Is Now. <i>Journal of Clinical Oncology</i> , 2019, 37, 2177-2178.  | 0.8 | 10        |
| 57 | <i>FGFR2</i> -Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. <i>Oncologist</i> , 2019, 24, 1462-1468.   | 1.9 | 16        |
| 58 | When Inhibitor MET Biomarker: Postmortem or Initium Novum?. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.   | 1.5 | 3         |
| 59 | Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 7098-7112.  | 3.2 | 142       |
| 60 | 386 HIGH NUMBERS OF PORTAL VENOUS CIRCULATING TUMOR CELLS ACQUIRED VIA EUS PROVIDE PROGNOSTIC ASSISTANCE FOR PROGRESSION FREE SURVIVAL IN PANCREATICOBILIARY CANCERS. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB78-AB79.                                      | 0.5 | 0         |
| 61 | Bemarituzumab with modified FOLFOX6 for advanced <i>FGFR2</i> -positive gastroesophageal cancer: FIGHT Phase III study design. <i>Future Oncology</i> , 2019, 15, 2073-2082.  | 1.1 | 55        |
| 62 | Keeping Checkpoint Inhibitors in Check. <i>JAMA Network Open</i> , 2019, 2, e192546.  | 2.8 | 9         |
| 63 | Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e88-e95.  | 1.8 | 17        |
| 64 | Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019, 22, 828-837. | 2.7 | 181       |
| 65 | Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas. <i>Cancer Discovery</i> , 2019, 9, 166-168.  | 7.7 | 4         |
| 66 | Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. <i>Oncologist</i> , 2019, 24, 1340-1347.  | 1.9 | 73        |
| 67 | Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. <i>Oncologist</i> , 2019, 24, 475-482.  | 1.9 | 23        |
| 68 | Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2403-2413.   | 3.2 | 40        |
| 69 | A <i>UGT1A1</i> genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. <i>Cancer</i> , 2019, 125, 1629-1636.   | 2.0 | 27        |
| 70 | Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 91-91.   | 0.8 | 10        |
| 71 | Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i> -Amplified Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 696-713.  | 7.7 | 107       |
| 72 | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.  | 3.4 | 1,350     |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 37-48.  | 7.7  | 248       |
| 74 | Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2018, 14, 417-430.   | 1.1  | 55        |
| 75 | Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. <i>Nature Medicine</i> , 2018, 24, 968-977.  | 15.2 | 196       |
| 76 | Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4030-4030.   | 0.8  | 9         |
| 77 | FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4135-TPS4135.   | 0.8  | 3         |
| 78 | Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).. <i>Journal of Clinical Oncology</i> , 2018, 36, 140-140.  | 0.8  | 13        |
| 79 | Circulating tumor DNA (ctDNA) landscape and prognostic implications in advanced gastroesophageal adenocarcinoma (GEC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 45-45.  | 0.8  | 5         |
| 80 | Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS198-TPS198.  | 0.8  | 9         |
| 81 | A phase 2 trial of CRS-207 and pembrolizumab in adults with recurrence of metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS200-TPS200.   | 0.8  | 0         |
| 82 | Safety and tolerability of 5-FU, irinotecan (IRI), and nab-paclitaxel (FOLFIRABRAX) with genotype-guided dosing of IRI in previously untreated patients with advanced gastrointestinal (GI) malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 423-423.   | 0.8  | 0         |
| 83 | Analysis of DNA damage response (DDR) genes and tumor mutational burden (TMB) across 17,486 carcinomas of the tubular GI tract: Implications for therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 43-43.   | 0.8  | 0         |
| 84 | Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4063-4063.   | 0.8  | 0         |
| 85 | Safety and tolerability of FOLFIRABRAX [5-Fluourouracil (5-FU), irinotecan (IRI), and nab-paclitaxel (NP)] with genotype-guided dosing of IRI in previously untreated advanced gastrointestinal (GI) cancer patients (pts): A multicenter trial of the University of Chicago Personalized Cancer Care Consortium.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16241-e16241. | 0.8  | 0         |
| 86 | It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 475-477.   | 0.8  | 25        |
| 87 | A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2017, 22, 264-271.   | 1.9  | 45        |
| 88 | Novel Targeted Therapies for Esophagogastric Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 293-312.   | 0.6  | 14        |
| 89 | Update on Gastroesophageal Adenocarcinoma Targeted Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 511-527.  | 0.9  | 15        |
| 90 | MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. <i>Cancer</i> , 2017, 123, 1061-1070.  | 2.0  | 32        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1467-1482. | 5.1 | 265       |
| 92  | A Subgroup Cluster-Based Bayesian Adaptive Design for Precision Medicine. <i>Biometrics</i> , 2017, 73, 367-377.   | 0.8 | 13        |
| 93  | KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4003.   | 0.8 | 134       |
| 94  | Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4067-4067.   | 0.8 | 10        |
| 95  | A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GE) junction or gastric (G) cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS219-TPS219.  | 0.8 | 9         |
| 96  | Molecular profiling of advanced pancreatic cancer (PC) patients from a phase I/II study using circulating tumor DNA.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4124-4124.   | 0.8 | 0         |
| 97  | Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4068-4068.  | 0.8 | 0         |
| 98  | How can next-generation diagnostics aid pancreatic adenocarcinoma treatment?. <i>Future Oncology</i> , 2016, 12, 585-588.  | 1.1 | 3         |
| 99  | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2016, 45, 370-375.   | 0.5 | 175       |
| 100 | Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 503-507.   | 2.3 | 9         |
| 101 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 717-726.  | 5.1 | 943       |
| 102 | Biliary cancer: Utility of next-generation sequencing for clinical management. <i>Cancer</i> , 2016, 122, 3838-3847.   | 2.0 | 289       |
| 103 | A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. <i>Investigational New Drugs</i> , 2016, 34, 319-328.  | 1.2 | 17        |
| 104 | Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. <i>Gastric Cancer</i> , 2016, 19, 1066-1079.  | 2.7 | 40        |
| 105 | Next-Generation Companion Diagnostics: Promises, Challenges, and Solutions. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 11-13.   | 1.2 | 29        |
| 106 | Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies. <i>Oncologist</i> , 2015, 20, 499-507.   | 1.9 | 64        |
| 107 | Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4284-4292.  | 0.8 | 431       |
| 108 | Expansion platform type II: testing a treatment strategy. <i>Lancet Oncology</i> , The, 2015, 16, 1276-1278.   | 5.1 | 13        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6496-505. | 3.3 | 313       |
| 110 | Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. <i>Molecular Oncology</i> , 2015, 9, 967-996.  | 2.1 | 119       |
| 111 | Tumor genome analysis includes germline genome: Are we ready for surprises?. <i>International Journal of Cancer</i> , 2015, 136, 1559-1567.   | 2.3 | 73        |
| 112 | Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue. <i>PLoS ONE</i> , 2014, 9, e100586.        | 1.1 | 52        |
| 113 | Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2014, 20, 1666-1675.                 | 3.2 | 61        |
| 114 | New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing. <i>Oncologist</i> , 2014, 19, 235-242.   | 1.9 | 371       |
| 115 | A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. , 2013, 1, 8.  |     | 30        |
| 116 | Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. <i>Journal of Hematology and Oncology</i> , 2013, 6, 66.   | 6.9 | 18        |
| 117 | Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. <i>PLoS ONE</i> , 2013, 8, e54014.                                      | 1.1 | 174       |
| 118 | Gastroesophageal cancer: focus on epidemiology, classification, and staging. <i>Discovery Medicine</i> , 2013, 16, 103-111.   | 0.5 | 44        |
| 119 | Differential expression of RON in small and non-small cell lung cancers. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 841-851.   | 1.5 | 32        |
| 120 | Toward personalized treatment of advanced biliary tract cancers. <i>Discovery Medicine</i> , 2012, 14, 41-57.   | 0.5 | 29        |
| 121 | Personalized Colon Cancer Care in 2010. <i>Seminars in Oncology</i> , 2011, 38, 284-308.  | 0.8 | 35        |
| 122 | Molecular Profiling of Cancer—The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic. <i>Seminars in Oncology</i> , 2011, 38, 173-185. | 0.8 | 61        |
| 123 | RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2011, 12, 9-46.  | 1.5 | 79        |
| 124 | Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence. <i>Cancer Discovery</i> , 2011, 1, 573-579.  | 7.7 | 105       |
| 125 | A survey of the population genetic variation in the human kinome. <i>Journal of Human Genetics</i> , 2009, 54, 488-492.   | 1.1 | 1         |
| 126 | Myelodysplastic syndromes: A comprehensive review. <i>Blood Reviews</i> , 2005, 19, 301-319.  | 2.8 | 68        |